BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial was designed to examine the efficacy of a brief versus a standard prolonged (18 hours) infusion of eptifibatide in preventing troponin I release following successful coronary stenting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardiology Research UBC
• Collaborator: University of British Columbia
• Treatments: Eptifibatide; Polystyrene sulfonic acid

Criteria

Inclusion Criteria:

• Male and non-pregnant female subjects

• 18 years of age or older

• Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight [LMW]) and eptifibatide

• Had a successful PCI procedure with at least one stent deployed

• Availability of a hospital bed

Exclusion Criteria:

• Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin)

• High risk patients:

• Acute ST elevation MI < 48 hours (either direct PCI or rescue PCI)

• Unprotected left main PCI

• Obvious large thrombus on angiography

• Use of rotablation, atherectomy, or thrombectomy devices

• Unsatisfactory PCI results:

• Final thrombolysis in myocardial infarction (TIMI) flow < 3

• High grade dissection (> type B, if not completely resolved at completion of PCI)

• Evident or suspected thrombus

• Distal embolization

• Suboptimal stenting (> 20% residual stenosis)

• Side branch closure (≥ 1.5 mm branch or with associated symptoms)

• Abrupt closure during procedure (if prolonged > 15 min or not resolved at completion of PCI)

• Clinical instability

• Prolonged ischemia during PCI (> 15 min)

• Increased hazard of eptifibatide infusion:

• Unsatisfactory deployment of a closure device (if used)

• Large peri-procedure hematoma making the continuation of eptifibatide hazardous

• Any condition that will increase the hazard of continuing eptifibatide

• Operator discretion

• No informed consent

• Active participation in other research studies (unless with special exemption)